Navigation Links
Taligen Therapeutics Secures Series B Financing
Date:2/1/2008

AURORA, Colo., Feb. 1 /PRNewswire/ -- Taligen Therapeutics, Inc. today announced it anticipates receiving up to $65 million in a tranched Series B financing. The financing was led by Alta Partners and Clarus Ventures with participation from existing investors, including Sanderling Ventures, Tango and High Country Venture.

"This Series B round represents not only an infusion of capital but the addition of two world class investor groups, Alta Partners and Clarus Ventures, represented on our Board respectively by Edward Hurwitz and Nicholas Galakatos, PhD," said Timothy Mills, PhD, Chairman of the Board of Taligen. "The progress made since our original investment in 2005 now allows us to develop multiple products to control the alternative pathway of complement activation. With this additional funding, we expect to move into clinical development with all of our lead candidates."

About Taligen: Founded in 2004, Taligen Therapeutics, Inc. is a development-stage biotechnology company with novel technology and expertise focused on modulation and control of the complement system. The complement system is believed to be a critical component in the initiation of inflammation. Complement system activation is characteristic of many human diseases, including asthma, macular degeneration, rheumatoid arthritis and immune renal disease.

Taligen's lead products are monoclonal antibodies and recombinant fusion proteins which target key factors in the alternative complement pathway. These products are in preclinical stages of development to treat systemic as well as local inflammatory conditions.

The Company was founded by Drs. Woodruff Emlen and V. Michael Holers based on technology and intellectual property predominantly from the University of Colorado at Denver and Health Sciences Center (UCDHSC) and partnering institutions. Dr. Holers is currently Professor of Medicine at UCDHSC and Dr. Emlen is a former Professor of Medicine and Immunology at U
'/>"/>

SOURCE Taligen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
3. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
4. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
5. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
6. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
10. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
11. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Columbia, PA (PRWEB) May 06, 2015 ... the most comprehensive lines of standard and custom ... Known for its innovative engineering and design, robust construction, ... chambers is designed to meet all of your temperature, ... to announce the addition of the TPS Smart 1.0 ...
(Date:5/6/2015)... 6, 2015 Whitefox ( ... today that it has signed an agreement with  ... PEIX ) for the delivery of an industrial scale membrane ... consumption of water, energy and emissions in ... This project is fully aligned with ...
(Date:5/5/2015)...  Blueprint Medicines (NASDAQ: BPMC ) today ... of 9,367,708 shares of common stock at a ... shares of common stock issued upon the full ... purchase additional shares. The gross proceeds from the ... $168.6 million, before underwriting discounts and estimated offering expenses. ...
(Date:5/5/2015)... Hayden-McNeil is pleased to announce they ... for smaller courses. This program is specifically designed for ... , “I’m very excited about offering our publishing ... said Jeff McCarthy, Hayden-McNeil president. “By working with more ... to make education both more effective and affordable.” , ...
Breaking Biology Technology:The TPS 3.5” Smart 1.0 Controller Raises the Tech Standard on Environmental Test Chambers 2Whitefox Signs Agreement With Pacific Ethanol Inc. 2Blueprint Medicines Announces Closing of Initial Public Offering 2Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2
... ... attracts investors, COLUMBUS, Ohio, Aug. ... for venture capital investments in biotech innovation and,business growth, according ... markets the state for capital,investment. The report, released by BioEnterprise, ...
... Barr,Pharmaceuticals, Inc. (NYSE: BRL ) today ... a challenge of the patent listed by,Warner Chilcott ... (norethindrone and ethinyl estradiol) chewable oral contraceptive. The,Company ... an Abbreviated New Drug,Application (ANDA) containing a paragraph ...
... Keck Graduate Institute,(KGI) today announced the election of ... M. Burzik, chief executive officer of Kinetic Concepts,Inc.; ... at,Gilead Sciences; and Peter Barton Hutt, senior counsel ... of leaders in business, industry and education who,have ...
Cached Biology Technology:Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry 2Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 2Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 3KGI Elects Three New Members to Board of Trustees 2
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... the IODP Arctic Coring Expedition (ACEX) is making news with ... of Nature, an article by several of the expedition scientists ... warm, unusually wet, and ice-free up to the time the ... Earth's atmosphere ?a period calculated to have occurred 55 million ...
... evolved 7 million years ago, the more advanced species ... researchers believe can effectively block the HIV-1 virus from ... quickly to overcome antiviral compounds designed to prevent infections. ... Cole of UCF's Burnett College of Biomedical Sciences has ...
... known to count the days until spring. Now, scientists have ... scientists here today (Aug. 9) at a meeting of the ... Amasino described studies that have begun to peel back some ... bloom at the optimal time of year. , "Flowering at ...
Cached Biology News:Arctic coring expedition continues to yield new clues 2Defense peptide found in primates may block some human HIV transmissions 2Defense peptide found in primates may block some human HIV transmissions 3Genetic snooze button governs timing of spring flowers 2Genetic snooze button governs timing of spring flowers 3
... General description: Designed for use with ... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. Comp Dim: ...
... pTriEx™ vectors combine the proven features of ... systems and provides all of the benefits ... one vector backbone. The pTriEx vectors have ... target genes in all three expression systems. ...
... is a complete, flexible system designed ... samples, as is frequently required in ... around Instechs miniature Clark-style polarographic electrode. ... in diameter (3.2 mm), it is ...
... The GSTTag Monoclonal Antibody is a ... affinity to the 26 kDa glutathione-S-transferase ... This purified antibody is suitable for ... sequence expressed in E. coli , ...
Biology Products: